CRT to license CTx’s FAK inhibitor programmes bringing treatment hope for triple-negative breast cancer

Cancer Research Technology, (CRT), the commercial arm of Cancer Research UK, is entering into two licences with Cancer Therapeutics CRC (CTx), an Australian cancer drug and development company, to commercialise CTx's pre-clinical focal adhesion kinase (FAK) inhibitor programmes. Cancer Research Technology, (CRT), the commercial arm of Cancer Research UK, is entering into two licences with Cancer Therapeutics CRC (CTx), an Australian cancer drug and development company, to commercialise CTx's pre-clinical focal adhesion kinase (FAK) inhibitor programmes.

15 August 2012

Cancer Research Technology and ADC Therapeutics join forces on drug conjugates

Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT) announce today that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT’s ‘warhead’ and linker chemistries. Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT) announce today that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT’s ‘warhead’ and linker chemistries.

6 July 2012

Cancer Research Technology and BioInvent enter oncology collaboration

Cancer Research Technology Ltd (CRT), the commercial arm of Cancer Research UK, and BioInvent International AB (OMXS: BINV) announced today that they have entered a collaboration with Queen Mary, University of London, to identify new therapeutic antibodies in oncology. Cancer Research Technology Ltd (CRT), the commercial arm of Cancer Research UK, and BioInvent International AB (OMXS: BINV) announced today that they have entered a collaboration with Queen Mary, University of London, to identify new therapeutic antibodies in oncology.

12 June 2012

CRT and the EIF unveil innovative Ј50M cancer fund to bridge development gap in the UK

Cancer Research Technology, (CRT) Cancer Research UK's commercial arm, and the European Investment Fund (EIF) have joined together to create a Ј50M investment fund to bridge the funding gap in the UK between cancer drug discovery and early development. Cancer Research Technology, (CRT) Cancer Research UK's commercial arm, and the European Investment Fund (EIF) have joined together to create a Ј50M investment fund to bridge the funding gap in the UK between cancer drug discovery and early development.

29 March 2012

CRT unveils 'screen test' for potential drugs to treat oestrogen positive breast cancer

Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer. Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.

5 March 2012

CRT spins out company to develop cancer surgery machine to melt tumours

Cancer Research Technology, the commercial arm of Cancer Research UK, has today launched Acublate Limited, a spin-out company which will develop a next-generation High Intensity Focused Ultrasound (HIFU) surgery device to treat a range of solid tumour types. Cancer Research Technology, the commercial arm of Cancer Research UK, has today launched Acublate Limited, a spin-out company which will develop a next-generation High Intensity Focused Ultrasound (HIFU) surgery device to treat a range of solid tumour types.

26 January 2012

• Science & Technology

Cancer Research Technology appoints new chairman to its board of directors

Cancer Research Technology - the commercial arm of Cancer Research UK - today announced the appointment of Peter Chambrй as its new chairman. Cancer Research Technology - the commercial arm of Cancer Research UK - today announced the appointment of Peter Chambrй as its new chairman.

13 October 2011

Cancer Research Technology and Cancer Research UK establish lipid metabolism research team

Cancer Research Technology, Cancer Research UKїs commercial arm, has established a group of scientists with expertise in lipid metabolism ї getting energy from fats and making building blocks for cell growth ї to develop targets for potential new cancer drugs. Cancer Research Technology, Cancer Research UKїs commercial arm, has established a group of scientists with expertise in lipid metabolism ї getting energy from fats and making building blocks for cell growth ї to develop targets for potential new cancer drugs.

29 September 2011

MISSION Therapeutics, a new Cambridge-based spin-out company, secures Ј6m in Series A funding led by Sofinnova Partners

A team led by Professor Stephen Jackson together with Cancer Research Technology (Cancer Research UKїs commercial arm) and the University of Cambridge has today announced the launch of MISSION Therapeutics Ltd, with Series A funding from a top venture capital syndicate. A team led by Professor Stephen Jackson together with Cancer Research Technology (Cancer Research UKїs commercial arm) and the University of Cambridge has today announced the launch of MISSION Therapeutics Ltd, with Series A funding from a top venture capital syndicate.

25 August 2011

• Health & Medicine

Cancer Research Technology and Kurma Biofund to develop new antibody platform for translational research

Cancer Research Technology, the commercial arm of Cancer Research UK, and Paris-based venture capital firm, Kurma Life Sciences Partners (Kurma), have launched a spin-out company, BliNK Therapeutics Ltd, to generate monoclonal antibodies using a novel platform. Cancer Research Technology, the commercial arm of Cancer Research UK, and Paris-based venture capital firm, Kurma Life Sciences Partners (Kurma), have launched a spin-out company, BliNK Therapeutics Ltd, to generate monoclonal antibodies using a novel platform.

13 June 2011

• Health & Medicine

Cancer Research Technology and Affitech A/S sign exclusive antibody development deal

Cancer Research Technology, the commercial arm of Cancer Research UK, has signed a license agreement to grant antibody medicines company, Affitech A/S, (NASDAQ OMX: AFFI), exclusive rights to a CRT patent application and relevant know how to develop and use therapeutic antibodies that recognise and block the function of CCR4, a protein found on certain tumours - including early and late stage cervical cancer and oesophageal cancer. Cancer Research Technology, the commercial arm of Cancer Research UK, has signed a license agreement to grant antibody medicines company, Affitech A/S, (NASDAQ OMX: AFFI), exclusive rights to a CRT patent application and relevant know how to develop and use therapeutic antibodies that recognise and block the function of CCR4, a protein found on certain tumours - including early and late stage cervical cancer and oesophageal cancer.

27 April 2011

• Science & Technology

Senectus Therapeutics and AstraZeneca collaborate to identify triggers to cell ageing

Senectus Therapeutics has signed a deal to screen a selection of AstraZenecaїs chemical compound library to identify those which trigger a key element of cancer cell ageing ї called senescence. Senectus Therapeutics has signed a deal to screen a selection of AstraZenecaїs chemical compound library to identify those which trigger a key element of cancer cell ageing ї called senescence.

23 March 2011